Determination of the exact molecular requirements for type 1 angiotensin receptor epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy

Hypertension

Volumn 57, Issue 5, 2011, Pages 973-980

  Smith, Nicola J ^a   Chan, Hsiu Wen ^a,b   Qian, Hongwei ^a   Bourne, Allison M ^a,b   Hannan, Katherine M ^c   Warner, Fiona J ^d   Ritchie, Rebecca H ^c   Pearson, Richard B ^c   Hannan, Ross D ^a   Thomas, Walter G ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d CENTENARY INSTITUTE   (Australia)

Author keywords

ADAM; angiotensin II; AT1A receptor; cardiomyocyte hypertrophy; EGFR; G protein; transactivation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BETA ARRESTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; PHOSPHOPEPTIDE; PHOSPHORUS 32;

ARTICLE; CELL GROWTH; GENE MUTATION; HEART HYPERTROPHY; HEART MUSCLE CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; TRANSACTIVATION;

ADAM PROTEINS; ANALYSIS OF VARIANCE; ANIMALS; ARRESTINS; CARDIOMEGALY; CELL ENLARGEMENT; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; IMMUNOPRECIPITATION; MATRIX METALLOPROTEINASES; MYOCYTES, CARDIAC; PHOSPHORYLATION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79955477865     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.166710     Document Type: Article

References (36)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566. (Pubitemid 20176696)
2. Smith NJ, Chan HW, Osborne JE, Thomas WG, Hannan RD. Hijacking epidermal growth factor receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy. Cell Mol Life Sci. 2004; 61:2695-2703. (Pubitemid 40022430)
3. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002;8:35-40. (Pubitemid 34101726)
4. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. Adenoviral-directed expression of the type 1a angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res. 2002;90:135-142. (Pubitemid 34627081)
5. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999;402:884-888.
6. Doan TN, Ali MS, Bernstein KE. Tyrosine kinase activation by the angiotensin II receptor in the absence of calcium signaling. J Biol Chem. 2001;276:20954-20958.
7. Seta K, Nanamori M, Modrall JG, Neubig RR, Sadoshima J. AT1 receptor mutant lacking heterotrimeric G protein coupling activates the src-ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem. 2002;277:9268-9277. (Pubitemid 34953009)
8. Seta K, Sadoshima J. Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin II-induced trans-activation of the epidermal growth factor receptor. J Biol Chem. 2003;278:9019-9026. (Pubitemid 36800380)
9. Zhai P, Galeotti J, Liu J, Holle E, Yu X, Wagner T, Sadoshima J. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ Res. 2006;99:528-536. (Pubitemid 44337825)
10. Adams JW, Brown JH. G-proteins in growth and apoptosis: lessons from the heart. Oncogene. 2001;20:1626-1634. (Pubitemid 32336851)
11. Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ, Frank GD, Inagami T, Higashiyama S, Thomas WG, Eckhart AD, Dempsey PJ, Eguchi S. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem. 2005;280:26592-26599. (Pubitemid 41022257)
12. Shah BH, Yesilkaya A, Olivares-Reyes JA, Chen HD, Hunyady L, Catt KJ. Differential pathways of angiotensin II-induced extracellularly reg-ulated kinase 1/2 phosphorylation in specific cell types: role of heparin-binding epidermal growth factor. Mol Endocrinol. 2004;18:2035-2048. (Pubitemid 39006507)
13. Ohtsu H, Higuchi S, Shirai H, Eguchi K, Suzuki H, Hinoki A, Brailoiu E, Eckhart AD, Frank GD, Eguchi S. Central role of Gq in the hypertrophic signal transduction of angiotensin II in vascular smooth muscle cells. Endocrinology. 2008;149:3569-3575. (Pubitemid 351919610)
14. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ. Differential kinetic and spatial patterns of/3-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem. 2004;279:35518-35525. (Pubitemid 39100552)
15. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, Le Corvoisier P, Violin JD, Wei H, Lefkowitz RJ, Rockman HA. ß-arrestin-mediated/31-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest. 2007;117:2445-2458.
16. Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, Rockman HA. ß-arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal. 2010;3:ra46.
17. Hunyady L, Bor M, Balla T, Catt KJ. Critical role of a conserved intramembrane tyrosine residue in angiotensin II receptor activation. J Biol Chem. 1995;270:9702-9705.
18. Thomas WG, Motel TJ, Kule CE, Karoor V, Baker KM. Phosphorylation of the angiotensin II (AT1a) receptor carboxyl terminus: a role in receptor endocytosis. Mol Endocrinol. 1998;12:1513-1524. (Pubitemid 30663434)
19. Thomas WG, Qian H, Chang CS, Karnik S. Agonist-induced phosphor-ylation of the angiotensin II (AT(1a)) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state. J Biol Chem. 2000;275:2893-2900. (Pubitemid 30082064)
20. Holloway AC, Qian H, Pipolo L, Ziogas J, Miura S, Karnik S, Southwell BR, Lew MJ, Thomas WG. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphor-ylation of type 1a angiotensin receptors. Mol Pharmacol. 2002;61: 768-777. (Pubitemid 34273156)
21. Tokumaru S, Higashiyama S, Endo T, Nakagawa T, Miyagawa JI, Yamamori K, Hanakawa Y, Ohmoto H, Yoshino K, Shirakata Y, Mat-suzawa Y, Hashimoto K, Taniguchi N. Ectodomain shedding of epi-dermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J Cell Biol. 2000;151:209-220.
22. Voskoboinik I, Fernando R, Veldhuis N, Hannan KM, Marmy-Conus N, Pearson RB, Camakaris J. Protein kinase-dependent phosphorylation of the Menkes copper p-type ATPase. Biochem Biophys Res Commun. 2003;303:337-342. (Pubitemid 36338246)
23. Fujii N, Tanaka M, Ohnishi J, Yukawa K, Takimoto E, Shimada S, Naruse M, Sugiyama F, Yagami K, Murakami K, Miyazaki H. Alterations of angiotensin II receptor contents in hypertrophied hearts. Biochem Biophys Res Commun. 1995;212:326-333.
24. Long CS, Kariya K, Karns L, Simpson PC Sympathetic modulation of the cardiac myocyte phenotype: studies with a cell-culture model of myocardial hypertrophy. Basic Res Cardiol. 1992;87(suppl 2):19-31. (Pubitemid 23081255)
25. Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S, Cooper S, Odenbach J, Finegan BA, Schulz R, Kassiri Z, Lopaschuk GD, Fernandez-Patron C Matrix metalloproteinase-7 and ADAM-12 (a dis-integrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation. 2009;119: 2480-2489.
26. Ali MS, Sayeski PP, Dirksen LB, Hayzer DJ, Marrero MB, Bernstein KE. Dependence on the motif YIPP for the physical association of JAK2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor. J Biol Chem. 1997;272:23382-23388. (Pubitemid 27392480)
27. Kai H, Griendling KK, Lassegue B, Ollerenshaw JD, Runge MS, Alexander RW. Agonist-induced phosphorylation of the vascular type 1 angiotensin II receptor. Hypertension. 1994;24:523-527. (Pubitemid 24296478)
28. Paxton WG, Marrero MB, Klein JD, Delafontaine P, Berk BC, Bernstein KE. The angiotensin II AT1 receptor is tyrosine and serine phosphory-lated and can serve as a substrate for the src family of tyrosine kinases. Biochem Biophys Res Commun. 1994;200:260-267.
29. Hunyady L, Bor M, Balla T, Catt KJ. Identification of a cytoplasmic Ser-Thr-Leu motif that determines agonist-induced internalization of the AT1 angiotensin receptor. J Biol Chem. 1994;269:31378-31382.
30. Garcia-Caballero A, Olivares-Reyes JA, Catt KJ, Garcia-Sainz JA. An-giotensin AT(1) receptor phosphorylation and desensitization in a hepatic cell line. Roles of protein kinase C and phosphoinositide 3-kinase. Mol Pharmacol. 2001;59:576-585. (Pubitemid 32179937)
31. SmithRD, Baukal AJ, Zolyomi A, Gaborik Z, Hunyady L, Sun L, Zhang M, Chen HC, Catt KJ. Agonist-induced phosphorylation of the endoge-nous AT1 angiotensin receptor in bovine adrenal glomerulosa cells. Mol Endocrinol. 1998;12:634-644. (Pubitemid 30659065)
32. Shah BH, Catt KJ. Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy. Trends Endocrinol Metab. 2004;15:241-243. (Pubitemid 39044195)
33. Kenakin T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci. 2003;24:346-354. (Pubitemid 37315526)
34. Billet S, Bardin S, Verp S, Baudrie V, Michaud A, Conchon S, Muffat-Joly M, Escoubet B, Souil E, Hamard G, Bernstein KE, Gasc JM, Elghozi JL, Corvol P, Clauser E. Gain-of-function mutant of angiotensin II receptor, type 1a, causes hypertension and cardiovascular fibrosis in mice. J Clin Invest. 2007;117:1914-1925. (Pubitemid 47036325)
35. Suzuki H, Kimura K, Shirai H, Eguchi K, Higuchi S, Hinoki A, Ishimaru K, Brailoiu E, Dhanasekaran DN, Stemmle LN, Fields TA, Frank GD, Autieri MV, Eguchi S. Endothelial nitric oxide synthase inhibits G12/13 and rho-kinase activated by the angiotensin II type-1 receptor: Impli-cation in vascular migration. Arterioscler Thromb Vasc Biol. 2009;29: 217-224.
36. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by ß-arrestins. Science. 2005;308:512-517.